U.S. Serial No. 10/773,790 Eocket Number: QA0280-NP Response to O.A. of July 26, 2006

REMARKS

Status of the Claims

Claims 1-20 were pending.

Claims 2-17 and 19-20 have been canceled.

Claims 1 and 18 were amended and remain pending.

Reconsideration is respectfully requested.

Amendments to the Claims

Claims 1 and 18 were amended to teach the subject matter elected pursuant to the Restriction Requirement.

Claims 2-17 and 19-20 were canceled as being drawn to non-elected subject matter.

Applicants believe that the present amendments do not introduce new matter, are fully supported by the specification and priority document, and do not broaden the scope of the claims.

Election/Restrictions

The Examiner has stated that claims 1-20 are drawn to products of the Formula depicted in claim 1, classified in various subclasses of classes 514, 544, 546 and 548. It is alleged that under 35 U.S.C. §121, an election of a single compound is required, including an exact definition of each substitution on the base molecule (Formula (I)), wherein a single member at each substituent group or moiety is selected. Applicants traverse this rejection because numerous examples disclosed in the instant specification support the teaching of the numerous groups in the claims. But, applicants will proceed to elect a single compound in order to advance this case to prosecution. Hence, claim 1 has been amended to teach a single elected compound of Formula I. Claim 18 has been amended to depend from claim 1 and is within the elected group.

Applicants reserve the right to file divisional applications covering the compounds of the non-elected subject matter.

NO. 8513 P. 8 Page 7 of 7

U.S. Scrial No. 10/773,790 Docket Number: QA0280-NP Response to O.A. of July 26, 2006

<u>Fees</u>

If it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

SUMMARY

In view of the foregoing comments and amendments, applicants kindly request reconsideration of the application. Applicants believe the case is now in condition for allowance and respectfully request the Examiner to pass the case to issue at an early date.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-4931

Date: August 25, 2006